Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results [Yahoo! Finance]
Altamira Therapeutics Ltd. - Common Shares (CYTO)
Company Research
Source: Yahoo! Finance
RNA delivery business progressing with new collaborations, potential new applications Partnering of legacy assets underway as Company transitions to focused RNA delivery technology provider Achieved 85% reduction in net loss to CHF 3.9 million and eliminated financial debt Finished year with shareholders' equity of CHF 6.5 million, improved by CHF 14.8 million HAMIL TON, BERMUDA -- April Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its full year 2023 financial results. "Altamira emerged from the 2023 business year as a stronger and more focused company," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman, and CEO. "We keep progressing with our RNA delivery business, concluding recently our second collaboration agreement with another exciting biotech company. With the recent partial
Show less
Read more
Impact Snapshot
Event Time:
CYTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTO alerts
High impacting Altamira Therapeutics Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
CYTO
News
- Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation [Yahoo! Finance]Yahoo! Finance
- Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationGlobeNewswire
- Altamira reports publication of positive results from NASAR clinical trial with Bentrio [Seeking Alpha]Seeking Alpha
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal [Yahoo! Finance]Yahoo! Finance
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalGlobeNewswire
CYTO
Sec Filings
- 4/22/24 - Form 20-F/A
- 4/18/24 - Form EFFECT
- 4/17/24 - Form 424B4
- CYTO's page on the SEC website